Argatroban as a potential anticoagulant in cardiopulmonary bypass-studies in a dog model

被引:18
作者
Sakai, M
Ohteki, H
Narita, Y
Naitoh, K
Natsuaki, M
Itoh, T
机构
[1] Saga Med Sch, Dept Cardiovasc Thorac Surg, Saga 840, Japan
[2] Saga Prefectural Hosp KOSEIKAN, Dept Cardiac Surg, Saga 840, Japan
来源
CARDIOVASCULAR SURGERY | 1999年 / 7卷 / 02期
关键词
argatroban; cardiopulmonary bypass; thrombin inhibitor;
D O I
10.1016/S0967-2109(98)00119-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Argatroban is a selective thrombin inhibitor synthesized in Japan, Argatroban, which has a high affinity for thrombin, and markedly inhibits thrombin-induced reactions, has been used in patients with artherosclerosis obliterans. The efficiency of argatroban, instead of heparin, as an anticoagulant in dog models of cardiopulmonary bypass was explored. In the first study, argatroban was administered as a bolus plus infusion for 1 h during cardiopulmonary bypass at doses of 1.0 mg + 10 mu g/kg per min, 2.0 mg + 10 mu g/kg per min and 3.0 mg + 10 mu g/kg per min (n = 2 per group), Activated clotting time and arterial gas analyses were performed beforehand and 10 min thereafter, In the second study, there were four groups, In the first group (n = 5), no coated extracorporeal circuit was used and heparin (2 mg/kg) was used as an anticoagulant, In the second group (n = 5), a coated extracorporeal circuit was used and heparin was used (2 mg/kg) as an anticoagulant, In the third group (n = 3), no coated extra-corporeal circuit was used and argatroban (2.0 mg + 10 mu g/kg per min) was used as an anticoagulant. In the fourth group (n = 5), a coated extracorporeal circuit was used and argatroban was used (2.0 mg + 10 mu g/kg per min) as an anticoagulant, All animals were perfused for 120 min at 40 ml/kg per minute. Platelet count, activated clotting time, thrombin-antithrombin III complex, antithrombin III, fibrinogen, fibrinogen degradation products and C3a were measured to evaluate platelet, coagulofibrinolytic and the complement system. Activated clotting time Values and the effect of argatroban during cardiopulmonary bypass indicated a dose-dependent response, The next highest dosing group (2.0 mg + 1.0 mu g/kg per minute) had activated clotting time values of 250-300 seconds during cardiopulmonary bypass, and fell after reaching near-normal levels within 60 minutes, No clots were noted in the extracorporeal circuit, The argatroban group showed lower levels in their coagulofibrinolytic system compared with the heparin group. The platelet count remained at a high level in the argatroban group. It is concluded that the combination of heparinized cardiopulmonary bypass circuits, and the use of argatroban as an anticoagulant, is safe and reduces the activation of coagulation and fibrinolytic systems and preserves platelet count. (C) 1999 The International Society for Cardiovascular Surgery. Published by Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:187 / 194
页数:8
相关论文
共 20 条
[1]  
BERRY CN, 1994, THROMB DIATH HAEMO, V3, P381
[2]   HEPARIN-COATED CIRCUITS REDUCE THE INFLAMMATORY RESPONSE TO CARDIOPULMONARY BYPASS [J].
GU, YJ ;
VANOEVEREN, W ;
AKKERMAN, C ;
BOONSTRA, PW ;
HUYZEN, RJ ;
WILDEVUUR, CRH .
ANNALS OF THORACIC SURGERY, 1993, 55 (04) :917-922
[3]  
HARKER LA, 1980, BLOOD, V56, P824
[4]  
Herrman, 1996, J Thromb Thrombolysis, V3, P367
[5]  
KAWADA T, 1992, ARTIF ORGAN TODAY, V2, P177
[6]   THE COMBINATION OF THROMBIN INHIBITOR AND THROMBOXANE SYNTHASE INHIBITOR ON EXPERIMENTAL THROMBOSIS AND BLEEDING [J].
KAWAI, H ;
TAMAO, Y .
THROMBOSIS RESEARCH, 1995, 80 (05) :429-434
[7]   HEPARIN CAUSES PLATELET DYSFUNCTION AND INDUCES FIBRINOLYSIS BEFORE CARDIOPULMONARY BYPASS [J].
KHURI, SF ;
VALERI, CR ;
LOSCALZO, J ;
WEINSTEIN, MJ ;
BIRJINIUK, V ;
HEALEY, NA ;
MACGREGOR, H ;
DOURSOUNIAN, M ;
ZOLKEWITZ, MA .
ANNALS OF THORACIC SURGERY, 1995, 60 (04) :1008-1014
[8]   SELECTIVE-INHIBITION OF THROMBIN BY (2R,4R)-4-METHYL-1-[N2-[(3-METHYL-1,2,3,4-TETRAHYDRO-8-QUINOLINYL)SULFONYL]-L-ARGINYL)]-2-PIPERIDINECARBOXYLIC ACID [J].
KIKUMOTO, R ;
TAMAO, Y ;
TEZUKA, T ;
TONOMURA, S ;
HARA, H ;
NINOMIYA, K ;
HIJIKATA, A ;
OKAMOTO, S .
BIOCHEMISTRY, 1984, 23 (01) :85-90
[9]  
KUKUK O, 1986, AM J HEMATOL, V23, P223
[10]  
Matsuo, 1995, J Thromb Thrombolysis, V2, P131, DOI 10.1007/BF01064381